Prognostic and predictive markers of malignant melanoma

Malignant melanoma biologically can be divided into non-metastatic and metastatic forms which cannot be predicted precisely using classical clinicopathological parameters, therefore studies on novel genetic or protein markers are abundant in the literature. These studies did not result in clinically...

Full description

Saved in:
Bibliographic Details
Published inMagyar onkologia Vol. 57; no. 2; p. 79
Main Authors Rásó, Erzsébet, Barbai, Tamás, Gyõrffy, Balázs, Tímár, József
Format Journal Article
LanguageHungarian
Published Hungary 01.06.2013
Subjects
Antineoplastic Agents - pharmacology
Biomarkers, Tumor - genetics
Cyclin-Dependent Kinase 2 - genetics
Diagnosis, Differential
Drug Resistance, Neoplasm - genetics
Humans
Interferons - drug effects
Interferons - metabolism
Interleukin-2 - metabolism
MART-1 Antigen - genetics
Melanoma - diagnosis
Melanoma - drug therapy
Melanoma - genetics
Molecular Targeted Therapy - trends
Osteopontin - genetics
Patient Selection
Peptide Fragments - genetics
Predictive Value of Tests
Prognosis
Proto-Oncogene Proteins B-raf - genetics
Proto-Oncogene Proteins c-bcl-2 - genetics
Proto-Oncogene Proteins c-kit - genetics
Skin Neoplasms - diagnosis
Skin Neoplasms - drug therapy
Skin Neoplasms - genetics
Online AccessGet more information

Cover

More Information
Summary:Malignant melanoma biologically can be divided into non-metastatic and metastatic forms which cannot be predicted precisely using classical clinicopathological parameters, therefore studies on novel genetic or protein markers are abundant in the literature. These studies did not result in clinically useful markers because mostly ignored the results of studies on the genetic basis of metastatic potential of malignant melanoma. Accordingly, the list of promising novel markers is short (BCL2, CDK2, MART-1, OPN). Similar to other solid malignancies, introduction of targeted therapy into clinical practice of melanoma turned the attention toward the genetic basis of resistance to chemo- and targeted therapies. These novel data could lead to the development of molecular diagnostics which can help in designing more effective therapeutic strategies of malignant melanoma.
ISSN:0025-0244